CLCN3

Across TCGA pan-cancer cohorts, CLCN3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CLCN3 data layer compared with 29 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CLCN3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CLCN3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

HNSC, UCEC, and LUAD are the cancer types where CLCN3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.791	0.510	<.001	61	view →
UCEC	OS	Median	II,III,IV	1.000	0.621	.012	14	view →
LUAD	DFS	Median	All	0.830	0.970	<.001	13	view →
CCRCC	OS	Median	All	0.783	0.901	.022	11	view →
LSCC	OS	Tertile	II,III,IV	0.835	0.910	.021	10	view →
PDAC	DFS	Quartile	III,IV	0.649	0.276	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CLCN3–HNSC (DFS)

Open the HNSC breakdown →